化痰祛湿活血方对非酒精性脂肪性肝炎大鼠ADPN/AMPK/ACC通路的影响

赵文霞; 闫乐; 邵明义; 张丽慧

doi:10.3969/j.issn.1001-5256.2017.05.029

化痰祛湿活血方对非酒精性脂肪性肝炎大鼠ADPN/AMPK/ACC通路的影响

DOI: 10.3969/j.issn.1001-5256.2017.05.029

河南中医药大学第一附属医院脾胃肝胆病科

基金项目:

河南省中医临床学科领军人才培育项目；国家自然基金(81473651)；

详细信息

中图分类号: R285.5
计量
- 文章访问数: 390
- HTML全文浏览量: 11
- PDF下载量: 186
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Effect of Huatan Qushi Huoxue prescription on the ADPN/AMPK/ACC signaling pathway in rats with nonalcoholic steatohepatitis

Department of Splenic, Gastric, and Hepatobiliary Diseases, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Research funding:

摘要

摘要:
目的研究化痰祛湿活血方对非酒精性脂肪性肝炎（NASH）大鼠脂联素（ADPN）/腺苷酸活化蛋白激酶（AMPK）/乙酰辅酶A羧化酶（ACC）通路的影响。方法 72只SD大鼠随机分为空白组、模型组、对照组及高、中、低剂量组,除空白组外,其余5组以高脂饲料联合四环素腹腔注射建立NASH模型,造模第2周分别给予化痰祛湿活血方高、中、低剂量和多烯磷脂酰胆碱（易善复）胶囊对照治疗。实验结束时,观察肝匀浆游离脂肪酸（FFA）含量,ELISA及RT-q PCR法测肝组织ADPN、脂联素受体2（AdipoR2）、AMPK、ACC、肉毒碱棕榈酰转移酶1（CPT-1）的基因与蛋白表达。多组间数据比较采用方差分析,方差齐者进一步两组间比较采用LSD-t检验,方差不齐者采用Dunnett’s T3法。结果与对照组比较,高剂量组能明显降低肝匀浆FFA[（229.07±46.62）μmol/gprot vs（382.75±30.93）μmol/gprot]、肝组织ACC的基因（1.66±0.04 vs 2.40±0.37）、蛋白[（512.20±60.70）pg/g vs（756.72±61.21）pg/g]表达（P...
- 非酒精性脂肪性肝炎 /
- 化痰祛湿活血方 /
- 脂联素 /
- 腺苷酸活化蛋白激酶 /
- 乙酰Co A羧化酶
Abstract:
Objective To investigate the effect of Huatan Qushi Huoxue prescription on the adiponectin (ADPN) /adenosine monophosphate-activated protein kinase (AMPK) /acetyl-Co A carboxylase (ACC) signaling pathway in rats with nonalcoholic steatohepatitis (NASH) .Methods A total of 72 male Sprague-Dawley rats were randomly divided into blank group, model group, control group, and high-, middle-, and low-dose Huatan Qushi Huoxue prescription groups.All rats except those in the blank group were given high-fat diet combined with intraperitoneal injection of tetracycline to establish a rat model of NASH.At week 2 after model establishment, the Huatan Qushi Huoxue prescription groups were treated with high-, middle-, and low-dose Huatan Qushi Huoxue prescription, and polyene phosphatidylcholine (Yishanfu) capsules were given as control.At the end of the experiment, the content of free fatty acid (FFA) in liver homogenate was measured, and ELISA and RT-q PCR were used to measure the protein and mRNA expression of ADPN, adiponectin receptor-2 (AdipoR2) , AMPK, ACC, and carnitine palmitoyltransferase-1 (CPT-1) in liver tissue.An analysis of variance was used for comparison of data between multiple groups;the least significant difference t-test was used for comparison of data with homogeneity of variance between two groups, and the Dunnett's T3 method was used for comparison of data with heterogeneity of variance.Results Compared with the control group, the high-dose group had significant reductions in FFA level in liver homogenate (229.07±46.62 μmol/gprot vs 382.75 ±30.93 μmol/gprot, P<0.01) and mRNA and protein expression of ACC in liver tissue (mRNA:1.66±0.04 vs 2.40±0.37, P<0.01;protein:512.20±60.70 pg/g vs 756.72±61.21 pg/g, P<0.01) , as well as significant increases in the mRNA and protein expression of ADPN (mRNA:1.53±0.31 vs 0.75±0.11, P<0.01;protein:22.23±2.75 μg/g vs 14.01±2.17 μg/g, P<0.01) , AdipoR2 (mRNA:1.38±0.33 vs 0.61±0.09, P<0.01;protein:128.41±10.46 ng/g vs 94.62±6.88 ng/g, P<0.01) , AMPK (mRNA:1.43±0.39 vs 0.78±0.04, P<0.01;protein:1353.79±59.52 μg/g vs 1107.19±56.78 μg/g, P<0.01) , and CPT-1 (mRNA:1.39±0.31 vs 0.52±0.04, P<0.01;protein:175.54±9.91 U/g vs 128.74±12.74 U/g, P<0.01) .Conclusion Huatan Qushi Huoxue prescription can effectively activate the ADPN/AMPK/ACC signaling pathway, which may affect the β oxidation and synthesis of fatty acids and reduce fat deposition in hepatocytes.
- nonalcoholic steatohepatitis /
- Huata Qushi Huoxue recipe /
- adiponectin /
- amp-activated protein kinase /
- acetyl-CoA carboxylase

HTML全文

参考文献(15)

[1]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会肪肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[2]YOUNOSSI ZM, MANN PK, WYMER M.Reply to the letter to the editor:global epidemiology of non-alcoholic fatty liver disease (NAFLD) [J].Hepatology, 2016, 64 (4) :1391-1393.

[3]BUECHLER C, WANNINGER J, NEUMEIER M.Adiponectin, a key adipokine in obesity related liver diseases[J].World J Gastroenterol, 2011, 17 (23) :2801-2811.

[4]LIANG HW, ZHAO WX.Effect of Xiaozhihugan Capsule on patients with non-alcoholi steatohepatitis, adiponectin and insulin resistance[J].Chin J Integr Tradit West Med Liver Dis, 2015, 25 (5) :264-266. (in Chinese) 梁浩卫, 赵文霞.消脂护肝胶囊对非酒精性脂肪性肝炎患者脂联素和胰岛素抵抗的影响[J].中西医结合肝病杂志, 2015, 25 (5) :264-266.

[5]ZHAO WX, YAN L, DUAN RZ.Effects of Huatan Qushi Huoxue Formula on hepatic pathological changes in nonalcoholic steatohepatitis model rats[J].J Tradit Chin Med, 2014, 55 (14) :1223-1226. (in Chinese) 赵文霞, 闫乐, 段荣章.化痰祛湿活血方对非酒精性脂肪性肝炎大鼠肝脏病理的影响[J].中医杂志, 2014, 55 (14) :1223-1226.

[6]ZHAO WX, YAN L, DUAN RZ.Effects of Huatan Qushi Huoxue Recipe on the expression of adiponectin and adiponectin receptors in rats with nonalcoholic steatohepatitis[J].China J Tradit Chin Med Pharma, 2014, 29 (9) :2975-2977. (in Chinese) 赵文霞, 闫乐, 段荣章.化痰祛湿活血方对非酒精性脂肪性肝炎大鼠脂联素及其受体的干预研究[J].中华中医药杂志, 2014, 29 (9) :2975-2977.

[7]ZHAO WX, LIU XT, YAN L.The impact of Ze Shen formulas particles on ADPN/AMPK signaling pathway in LO2 Steatosis[J].Chin Hepatol, 2014, 19 (6) :448-450. (in Chinese) 赵文霞, 刘雪涛, 闫乐.泽参颗粒对脂肪变LO2细胞ADPN/AMPK信号通路的影响[J].肝脏, 2014, 19 (6) :448-450.

[8]PAN Q, FAN JG.Animal model of high fat diet-induced nonalcoholic fatty liver disease[J].Int J Dig Dis, 2009, 29 (4) :255-257. (in Chinese) 潘勤, 范建高.高脂饮食诱导非酒精性脂肪性肝病动物模型的研究进展[J].国际消化病杂志, 2009, 29 (4) :255-257.

[9]SHEN C, GAO J, ZHAO CY.Animal models of non-alcoholic fatty liver disease:recent advances[J].World Chin J Dig, 2009, 17 (33) :3414-3419. (in Chinese) 申川, 高健, 赵彩彦.非酒精性脂肪性肝病动物模型研究进展[J].世界华人消化杂志, 2009, 17 (33) :3414-3419.

[10]NOORI M, JAFARI B, HEKMATDOOST A.Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation[J].J Sci Food Agric, 2016.[Epub ahead of print]

[11]TILG H.Adipocytokines in nonalcoholic fatty liver disease:key players regulating steatosis, inflammation and fibrosis[J].Current Pharmaceutical Design, 2010, 16 (17) :1893-1895.

[12]JUNG UJ, CHOI MS.Obesity and its metabolic complications:the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease[J].Int J Mol Sci, 2014, 15 (4) :6184-6223.

[13]FINELLI C, TARANTINO G.What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?[J].World J Gastroenterol, 2013, 19 (6) :802-812.

[14]MATSUNAMI T, SATO Y, ARIGA S, et al.Yukawa M Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model[J].Metabolism, 2011, 60 (6) :805-814.

[15]IDETA T, SHIRAKAMI Y, MIYAZAKI T, et al.The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice[J].Int J Mol Sci, 2015, 16 (12) :29207-29218.

施引文献

资源附件(0)

访问统计